331. 特発性多中心性キャッスルマン病 ［臨床試験数：18，薬物数：37（DrugBank：24），標的遺伝子数：30，標的パスウェイ数：140］
Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03864419 | October 24, 2019 | 4 November 2019 | Rituximab Hyaluronidase and Combination Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda | A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics Children, Adolescents, and Adults in Uganda | Burkitt Lymphoma;KSHV-associated Multicentric Castleman Disease;Diffuse Large B-Cell Lymphoma | Biological: Rituximab or Rituximab Hyaluronidase Human;Drug: Cyclophosphamide;Drug: Vincristine;Drug: Methotrexate;Drug: Doxorubicin;Drug: Doxorubicin Hydrochloride;Drug: Prednisone;Drug: Etoposide | Fred Hutchinson Cancer Research Center | National Cancer Institute (NCI) | Recruiting | 2 Years | N/A | All | 40 | Phase 1 | United States |
| 2 | JPRN-jRCT2071190029 | 09/10/2019 | 5 November 2019 | Sirolimus study in refractory idiopathic multicentric Castleman's disease | Randomized, double-blind, placebo-controlled, parallel-group trial of Sirolimus for Tocilizumab-resistant idiopathic multicentric Castleman disease. | idiopathic multicentric Castleman's disease Castleman's disease | Treatment: Sirolimus 2 mg po once/day. Control: Placebo given orally once daily | Atsushi Kawakami | Not Recruiting | >= 18age old | Not applicable | Both | 20 | Phase 2 | none | |
| 3 | NCT03933904 | September 25, 2019 | 14 October 2019 | Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease | A Phase II, Single-arm Open-label Multi-center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease | Castleman Disease;Castleman's Disease, Multicentric | Drug: Sirolimus | University of Pennsylvania | Recruiting | 18 Years | 80 Years | All | 24 | Phase 2 | United States | |
| 4 | NCT03982771 | January 1, 2019 | 24 June 2019 | BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) | Bortezomib, Cyclophosphamide and Dexamethasone (BCD) in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD) : a Prospective, Single-center, Single-arm, Phase-II Pilot Trial | Idiopathic Multicentric Castleman's Disease | Drug: Bortezomib;Drug: Cyclophosphamide;Drug: Dexamethason | Peking Union Medical College Hospital | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | China | |
| 5 | NCT03043105 | January 1, 2017 | 16 December 2017 | TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial | Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial | Multicentric Castleman Disease | Drug: Thalidomide, cyclophosphamide and prednisone | Peking Union Medical College Hospital | Recruiting | 18 Years | N/A | All | 55 | Phase 2 | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT02228512 | August 15, 2014 | 10 September 2018 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease) | Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease;Primary Effusion Lymphoma | Drug: Cyclophosphamide;Drug: Pomalidomide;Drug: Rituximab;Drug: Prednisone;Drug: Etoposide;Drug: Doxorubicin;Drug: Vincristine | National Cancer Institute (NCI) | Not recruiting | 18 Years | 99 Years | All | 0 | Phase 1/Phase 2 | United States | |
| 7 | NCT02080416 | July 2014 | 20 June 2016 | Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors | A Pilot Trial of Nelfinavir for the Lytic Activation and Treatment of Gammaherpesvirus-Related Tumors | Non-Hodgkin Lymphoma;Hodgkin Lymphoma;Kaposi Sarcoma;Gastric Cancer;Nasopharyngeal Cancer;EBV;Castleman Disease | Drug: Nelfinavir | Sidney Kimmel Comprehensive Cancer Center | Not recruiting | 18 Years | N/A | Both | 1 | Phase 0 | United States | |
| 8 | NCT01552434 | March 16, 2012 | 30 September 2019 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications | Advanced Malignant Neoplasm;Castleman Disease;Digestive System Carcinoma;Erdheim-Chester Disease;Lip and Oral Cavity Carcinoma;Lymphangioleiomyomatosis;Malignant Endocrine Neoplasm;Malignant Female Reproductive System Neoplasm;Malignant Male Reproductive System Neoplasm;Malignant Neoplasm;Malignant Respiratory Tract Neoplasm;Malignant Thoracic Neoplasm;Malignant Urinary System Neoplasm;Mesothelial Neoplasm;Metastatic Malignant Neoplasm;Metastatic Urothelial Carcinoma;Neurofibromatosis Type 2;Recurrent Adult Soft Tissue Sarcoma;Recurrent Breast Carcinoma;Recurrent Childhood Soft Tissue Sarcoma;Recurrent Digestive System Carcinoma;Recurrent Female Reproductive System Carcinoma;Recurrent Male Reproductive System Carcinoma;Recurrent Malignant Neoplasm;Recurrent Pharyngeal Carcinoma;Recurrent Thyroid Gland Carcinoma;Refractory Malignant Neoplasm;Soft Tissue Neoplasm;Stage III Breast Cancer AJCC v7;Stage III Pharyngeal Cancer;Stage IIIA Breast Cancer AJCC v7;Stage IIIB Breast Cancer AJCC v7;Stage IIIC Breast Cancer AJCC v7;Stage IV Breast Cancer AJCC v6 and v7;Stage IV Pharyngeal Cancer;Stage IVA Pharyngeal Cancer;Stage IVB Pharyngeal Cancer;Stage IVC Pharyngeal Cancer;Thyroid Gland Neoplasm | Biological: Bevacizumab;Biological: Cetuximab;Other: Laboratory Biomarker Analysis;Other: Pharmacological Study;Drug: Temsirolimus;Drug: Valproic Acid | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | Recruiting | N/A | N/A | All | 216 | Phase 1 | United States |
| 9 | NCT01441063 | September 13, 2011 | 11 November 2019 | Tocilizumab for KSHV-Associated Multicentric Castleman Disease | Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease | Castleman Disease;Castleman's Disease;Giant Lymph Node Hyperplasia | Drug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC) | National Cancer Institute (NCI) | Recruiting | 18 Years | N/A | All | 17 | Phase 2 | United States | |
| 10 | NCT01400503 | April 1, 2011 | 11 June 2018 | A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease | Multicentric Castleman's Disease | Drug: Siltuximab | Janssen Research & Development, LLC | Not recruiting | 18 Years | N/A | All | 60 | Phase 2 | United States;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2009-012380-34-GB | 18/05/2010 | 11 September 2012 | A study of the safety and efficacy of CNTO328 in combination with best supportive care compared to best supportive care in patients with Multicentric Castleman's Disease | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman’s Disease | Multicentric Castleman's disease MedDRA version: 14.1 Level: PT Classification code 10050251 Term: Castleman's disease System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Multicentric Castleman's disease MedDRA version: 14.1 Level: PT Classification code 10050251 Term: Castleman's disease System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Product Name: CNTO328 Product Code: CNTO328 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: NA CAS Number: NA Current Sponsor code: CNTO 328 Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100 and 400- Pharmaceutical form of the placebo: Powder for solution for infusion Route of administration of the placebo: Intravenous use Product Code: CNTO328 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: NA CAS Number: NA Current Sponsor code: CNTO 328 Other descriptive name: Chimeric murine human anti-IL-6 monoclonal antibody Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100 and 400- Pharmaceutical form of the placebo: Powder for solution for infusion Route of administration of the placebo: Intravenous use | Janssen-Cilag International N.V. | Authorised | Female: yes Male: yes | 78 | Hungary;Germany;Malaysia;Netherlands;France;Norway;Singapore;Hong Kong;Australia;Brazil;Israel;India;United Kingdom;Russian Federation;New Zealand;Canada;Egypt;Taiwan;Belgium;Korea, Republic of;China;Spain;United States | ||||
| 12 | NCT00891280 | February 2009 | 19 February 2015 | Dose-escalation Study of Oral CX-4945 | A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma | Advanced Solid Tumors;Breast Cancer;Inflammatory Breast Cancer;Castleman's Disease;Multiple Myeloma | Drug: CX-4945 oral formulation | Cylene Pharmaceuticals | Recruiting | 18 Years | N/A | Both | 55 | Phase 1 | United States | |
| 13 | NCT00361933 | December 2008 | 16 December 2017 | Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease | Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir | Giant Lymph Node Hyperplasia | Drug: Valganciclovir | University of Washington | Hoffmann-La Roche | Not recruiting | 18 Years | N/A | All | 0 | Phase 4 | United States |
| 14 | NCT01183598 | August 2006 | 14 November 2016 | A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment | Provision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab Treatment | Castleman's Disease | Drug: tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Not recruiting | 18 Years | N/A | Both | 3 | Phase 1 | United States | |
| 15 | NCT00412321 | May 2005 | 19 February 2015 | A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease | A Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease | Lymphoma, Non-Hodgkin;Multiple Myeloma;Giant Lymph Node Hyperplasia | Drug: CNTO 328 | Centocor, Inc. | Not recruiting | 18 Years | N/A | Both | 67 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT00092222 | October 28, 2004 | 11 November 2019 | Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity | Lymphoproliferative Disorder;HHV-8;Malignancy;HIV | Drug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin;Drug: Bortezomib;Drug: Valganciclovir;Drug: Doxorubicin;Drug: Vincristine;Drug: Cyclophosphamide;Drug: Filgrastim (G-CSF);Drug: Prednisone;Drug: Sirolimus;Other: Observation Only | National Cancer Institute (NCI) | Recruiting | 12 Years | 65 Years | All | 72 | Phase 2 | United States | |
| 17 | NCT00127569 | May 2003 | 19 February 2015 | Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy | Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB) | HIV Infections;Giant Lymph Node Hyperplasia | Drug: Rituximab | French National Agency for Research on AIDS and Viral Hepatitis | Hoffmann-La Roche | Not recruiting | 18 Years | N/A | Both | 25 | Phase 2 | |
| 18 | NCT00002652 | May 1995 | 19 February 2015 | Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease | A PHASE II PILOT STUDY OF SURAMIN IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA AND PATIENTS WITH CASTLEMAN'S DISEASE | Multiple Myeloma and Plasma Cell Neoplasm | Drug: suramin | University of Arkansas | National Cancer Institute (NCI) | Not recruiting | 18 Years | N/A | Both | Phase 2 | United States |